文献速递临床免疫临床生化

基于脂质体Aβ40肽检测抗Aβ自身抗体的阿尔茨海默病诊断

Alzheimer's disease diagnosis based on detection of autoantibodies against Aβ using Aβ40 peptide in liposomes.
PubMed 文献 · Clin Chim Acta · 2022-04-18

该研究构建了一种免疫传感器,将封装的Aβ40肽脂质体固定在丝网印刷碳电极上,用于检测血浆中抗Aβ40自身抗体。循环伏安法显示,特定抗体在0.1至10 μg/ml范围内引起伏安面积和电流增加;在患者脑脊液和血浆样本中,该方法可区分AD阳性与阴性样本。

要点

  • 免疫传感器可检测血浆中抗Aβ40自身抗体,实现AD无创诊断。
  • 循环伏安法下,抗体浓度0.1–10 μg/ml引起电流和伏安面积增加。
  • 脑脊液和血浆样本的伏安谱可区分AD阳性与阴性。

核心结论

  • 该方法可检测血浆中天然自身抗体,实现阿尔茨海默病的无创诊断,且方法简单易解读。

研究设计与样本

  • 研究构建免疫传感器:将Aβ40肽封装于DPPG脂质体,固定于聚乙烯亚胺修饰的丝网印刷碳电极。
  • 采用原子力显微镜和循环伏安法表征传感器组装,并检测抗Aβ40抗体及患者脑脊液和血浆样本。

主要发现

  • 原子力显微镜显示脂质体呈20至200 nm球状聚集体。
  • 传感器暴露于抗Aβ40抗体后,薄膜粗糙度增加约9 nm,提示免疫复合物形成。
  • 循环伏安法检测中,抗Aβ40抗体在0.1至10 μg/ml范围内引起伏安面积和0.45 V处电流增加,分别达3.2 µA.V和5.7 μA,对照系统在0.1 μg/ml以上几乎不变。
  • 患者脑脊液样本中,AD阳性与阴性样本的伏安面积差异为健康样本上误差条以上0.1 μA.V;血浆样本差异为0.6 μA.V。

临床怎么用

  • 该免疫传感器可作为AD无创诊断的潜在方法,通过检测血浆抗Aβ40自身抗体区分阳性与阴性样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia and affect more than 50 million people worldwide. Thus, there is a high demand by non-invasive methods for an early diagnosis. This work explores the AD diagnostic using the amyloid beta 1-40 (Aβ40) peptide encapsulated into dipalmitoyl phosphatidyl glycerol (DPPG) liposomes and immobilized on polyethylene imine previously deposited on screen-printed carbon electrodes to detect autoantibodies against Aβ40, a potential biomarker found in plasma samples. METHODS: The immunosensor assembly was accompanied by atomic force microscopy (AFM) images that showed globular aggregates from 20 to 200 nm corresponding liposomes and by cyclic voltammetry (CV) through increase of the voltammogram area each material deposited. After building the immunosensor, when it was exposed to antibody anti-Aβ40, there was an increase in film roughness of approximately 9 nm, indicating the formation of the immunocomplex. RESULTS: In the detection by CV, the presence of specific antibody, in the range of 0.1 to 10 μg/ml, resulted in an increase in the voltammograms area and current in 0.45 V reaching 3.2 µA.V and 5.7 μA, respectively, in comparison with the control system, which remained almost unchanged from 0.1 μg/ml. In patient samples, both cerebrospinal fluid (CSF) and plasma, was possible separated among positive and negative samples for AD using CV profile and area, with a difference of 0.1 μA.V from the upper error bar of healthy samples for CSF sample and 0.6 μA.V for plasma sample. CONCLUSIONS: These results showed the feasibility of the method employed for the non-invasive diagnostic of Alzheimer's disease detecting natural autoantibodies that circulate in plasma through a simple and easy-to-interpret method.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Monteiro JC, Yokomichi ALY, de Carvalho Bovolato AL, et al. Alzheimer's disease diagnosis based on detection of autoantibodies against Aβ using Aβ40 peptide in liposomes. Clin Chim Acta. 2022. PMID: 35447142. doi:10.1016/j.cca.2022.04.235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。